Deep Bio Inc., based in Seoul, South Korea, is an AI biotech company with in-house expertise in deep learning, pathology, life sciences, and pharmacotherapeutics. As the country’s first to obtain KFDA approval in AI-based cancer pathology, Deep Bio envisions a suite of AI-based digital IVDs (In Vitro Diagnostics) for cancers diagnosis and prognosis. Founded in 2015, Deep Bio Inc. continues to collaborate with top medical centers in Korea and the US on multiple cancers including prostate, breast, and bladder. Deep Bio values mutual respect and trust, and personal growth guided by self-management. With the latest funding in 2020, the company is growing in size and has recently expanded to AI-driven drug discovery and development, as well as digital health services.